Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeRestated

Delegating Authority to Operating Subsidiaries to Accelerate Decision-Making

First written in FY2022-Q1. 3 of 4 entries say "Restated". Latest entry: FY2024.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20242021: 120212022: 120222023: 120232024: 12024
Same theme, other companies
Autonomous Business Decision-Making Independent of the Parent CompanyA theme 40 companies write about · 4 as a headwind · 36 as a tailwind

The whole theme swung hardest in 2020: 2 of 18 companies on the "Worse" side.

31 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 40 companies compared. The sentences above are computed from all 40.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「We separate management from execution through the executive officer system: executive officers execute business operations, while directors focus exclusively on management and oversight.」

    The policy of separating management and oversight from business execution is reiterated.
  2. FY2023RestatedAnnual report

    「The holding company will focus on overseeing each operating company and formulating and implementing Group strategy, while business-level decisions will be completed by the operating companies.」

    持株会社と事業会社の役割分担および事業会社への意思決定移譲を再掲している。
  3. FY2022RestatedAnnual report

    「The holding company will focus on overseeing each operating company and formulating and implementing Group strategy, while business-level decisions will be completed by the operating companies.」

    The policy of separating the roles of the holding company and operating companies, with operating companies completing business-level decisions, is reiterated.
  4. FY2022-Q1First statedAnnual report

    「We aim to establish a structure that clearly defines the roles and responsibilities of each Group company and enables appropriate and timely responses to changes in the business environment. The holding company will specialize in overseeing each operating company and formulating and implementing Group strategy, while business-level decisions will be completed by the operating companies.」

    A management structure is described in which the roles of the holding company and operating companies are separated and business-level decisions are completed by the subsidiaries.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.